Discussion In the current trial, we could show an enhanced humoral and cellular immune response in patients with IMIDs and HCs after a third vaccination.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Mrak
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial - Nature Communications
Abstract Impaired response to COVID-19 vaccination is of particular concern in immunosuppressed patients. To determine the best vaccination strategy for this vulnerable group we performed a single center, 1:1 randomized blinded clinical trial. Patients who failed to seroconvert upon two mRNA vaccinations (BNT162b2 or mRNA-1273) are randomized to receive either a third dose of the same mRNA or the vector vaccine ChAdOx1 nCoV-19.
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study
Discussion In this open-label extension trial, we found an increase in seroconversion rates as well as in antibody levels after a fourth vaccination in rituximab-treated patients who mounted no or low antibody titers after their third vaccination. However, the antibody response was vastly diminished depending on the numbers of peripheral B-cells and the timing of the rituximab treatment in relation to the fourth vaccination. A modestly enhanced cellular immune response was observed.
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study
http://orcid.org/0000-0001-5321-6751Daniel Mrak1, http://orcid.org/0000-0001-8177-9949Elisabeth Simader1, Daniela Sieghart1, http://orcid.org/0000-0003-1526-4052Peter Mandl1, Helga Radner1, http://orcid.org/0000-0002-7976-0285Thomas Perkmann2, http://orcid.org/0000-0003-4605-2503Helmuth Haslacher2, Margareta Mayer3, Maximilian Koblischke3, Philipp Hofer4, Lisa Göschl1, http://orcid.org/0000-0001-8540-2831Felix Kartnig1, Thomas Deimel1, http://orcid.org/0000-0002-6685-8873Andreas...
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial
Abstract Background Polymyalgia rheumatica is the second most common inflammatory rheumatic disease of people >50 years. Glucocorticoid therapy is highly effective, but many patients require treatment for several years. Effective glucocorticoid sparing agents are still needed.
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial Free http://orcid.org/0000-0002-6122-7482Michael Bonelli1, http://orcid.org/0000-0001-5321-6751Daniel Mrak1, Selma Tobudic2, Daniela Sieghart1, Maximilian Koblischke3, http://orcid.org/0000-0003-1526-4052Peter Mandl1, Barbara Kornek4, http://orcid.org/0000-0001-8177-9949Elisabeth Simader1, Helga...
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial
Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial http://orcid.org/0000-0002-6122-7482Michael Bonelli1, Helga Radner1, http://orcid.org/0000-0002-6685-8873Andreas Kerschbaumer1, http://orcid.org/0000-0001-5321-6751Daniel Mrak1, Martina Durechova1, Jutta Stieger2, Rusmir Husic3, http://orcid.org/0000-0003-1526-4052Peter Mandl1, Josef S Smolen1, http://orcid.org/0000-0002-0173-0668Christian Dejaco3,4,...
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial Free http://orcid.org/0000-0002-6122-7482Michael Bonelli1, http://orcid.org/0000-0001-5321-6751Daniel Mrak1, Selma Tobudic2, Daniela Sieghart1, Maximilian Koblischke3, http://orcid.org/0000-0003-1526-4052Peter Mandl1, Barbara Kornek4, http://orcid.org/0000-0001-8177-9949Elisabeth Simader1, Helga...
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Free http://orcid.org/0000-0001-5321-6751Daniel Mrak1, Selma Tobudic2, Maximilian Koblischke3, Marianne Graninger3, Helga Radner1, Daniela Sieghart1, Philipp Hofer4, Thomas Perkmann5, http://orcid.org/0000-0003-4605-2503Helmuth Haslacher5, Renate Thalhammer5, Stefan Winkler2, http://orcid.org/0000-0002-2758-4400Stephan Blüml1, Karin Stiasny3, Judith H...
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response Free http://orcid.org/0000-0002-6122-7482Michael Markus Bonelli1, Daniel Mrak1, Thomas Perkmann2, Helmuth Haslacher2, http://orcid.org/0000-0003-2108-0030Daniel Aletaha1 1 Division of Rheumatology, Medical University of Vienna, Vienna, Austria 2 Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria Correspondence to Professor Daniel Aletaha,...
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Free http://orcid.org/0000-0001-5321-6751Daniel Mrak1, Selma Tobudic2, Maximilian Koblischke3, Marianne Graninger3, Helga Radner1, Daniela Sieghart1, Philipp Hofer4, Thomas Perkmann5, http://orcid.org/0000-0003-4605-2503Helmuth Haslacher5, Renate Thalhammer5, Stefan Winkler2, http://orcid.org/0000-0002-2758-4400Stephan Blüml1, Karin Stiasny3, Judith H...
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response Free http://orcid.org/0000-0002-6122-7482Michael Markus Bonelli1, Daniel Mrak1, Thomas Perkmann2, Helmuth Haslacher2, http://orcid.org/0000-0003-2108-0030Daniel Aletaha1 1Division of Rheumatology, Medical University of Vienna, Vienna, Austria 2Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria Correspondence to Professor Daniel Aletaha,...
Evaluation of sCD163 and sTWEAK in patients with stable peripheral arterial disease and association with disease severity as well as long-term mortality
Highlights • sCD163 is significantly elevated in symptomatic vs asymptomatic peripheral arterial disease. • sTWEAK showed an inverse association with all-cause and cardiovascular mortality in stable peripheral arterial disease. • Adding sTWEAK to the Cox-proportional hazards model of all-cause mortality resulted in a net reclassification improvement.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack